Abstract
The Toxicology Investigators Consortium (ToxIC) Registry was established by the American College of Medical Toxicology (ACMT) in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultation will be entered. The objective of this ninth annual report is to summarize the Registry’s 2018 data and activity with its additional 7043 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2018. Detailed data was collected from these cases and aggregated to provide information which included demographics, reason for medical toxicology evaluation, agent and agent class, clinical signs and symptoms, treatments and antidotes administered, mortality, and whether life support was withdrawn. A total of 51.5% of cases were female, 48% were male, and 0.6% transgender. Non-opioid analgesics were the most commonly reported agent class, followed by antidepressants and opioids. Acetaminophen was once again the most common agent reported. There were 106 fatalities, comprising 1.5% of all registry cases. Major trends in demographics and exposure characteristics remained similar to past years’ reports. Sub-analyses were conducted to describe exposures in elderly patients, addiction consultation practices, and risk factors for bupropion-induced seizures. The launch of the ToxIC Qualified Clinical Data Registry (TQCDR) is also described.
Similar content being viewed by others
References
Farrugia LA, Rhyee SH, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry-the 2017 Annual Report. J Med Toxicol. 2018;14(3):182–211.
Farrugia LA, Rhyee SH, Calello DP, et al. The Toxicology Investigators Consortium Case Registry-the 2016 Experience. J Med Toxicol. 2017;13(3):203–26.
Rhyee SH, Farrugia L, Wiegand T, et al. The toxicology investigators consortium case registry-the 2013 experience. J Med Toxicol. 2014;10(4):342–59.
Rhyee SH, Farrugia L, Campleman SL, Wax PM, Brent J, Toxicology Investigators C. The Toxicology Investigators Consortium Case Registry--the 2014 Experience. J Med Toxicol. 2015;11(4):388–409.
Farrugia LA, Rhyee SH, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry-the 2015 Experience. J Med Toxicol. 2016;12(3):224–47.
Wiegand TJ, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry--the 2011 experience. J Med Toxicol. 2012;8(4):360–77.
Wiegand T, Wax P, Smith E, Hart K, Brent J. The Toxicology Investigators Consortium Case Registry--the 2012 experience. J Med Toxicol. 2013;9(4):380–404.
Brent J, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry-the 2010 experience. J Med Toxicol. 2011;7(4):266–76.
Spencer MR, Warner M, Bastian BA, Trinidad JP, Hedegaard H. Drug Overdose Deaths Involving Fentanyl, 2011-2016. Natl Vital Stat Rep. 2019;68:3):1–19.
Thomas AA, Von Derau K, Bradford MC, Moser E, Garrard A, Mazor S. Unintentional Pediatric Marijuana Exposures Prior to and After Legalization and Commercial Availability of Recreational Marijuana in Washington State. J Emerg Med. 2019;56(4):398–404.
Ng PC, Banerji S, Graham J, Leonard J, Wang GS. Adolescent exposures to traditional and novel psychoactive drugs, reported to National Poison Data System (NPDS), 2007-2017. Drug Alcohol DependDrug Alcohol Depend. 2019;202:1–5.
Kang AM. Substances Involved in Suicidal Poisonings in the United States. Suicide Life Threat Behav. 2018.
Finkelstein Y, Hutson JR, Wax PM, Brent J. Toxicology Investigators Consortium Case R. Toxico-surveillance of infant and toddler poisonings in the United States. J Med Toxicol. 2012;8(3):263–6.
Acknowledgments
Toxicology Investigators Consortium (ToxIC) Study Group Collaborators:
Beauchamp GA, Beuhler MC, Boyle KL, Cannon RD, Carey JL, Carpenter J, Chenoweth JA, Colby DK, Eisenga BH, Fisher E, Ford JB, Fox LM, Ganetsky M, Gorodetsky R, Greene SC, Griswold MK, Harding SA, Hendrickson RG, Horowitz BZ, Hoyte C, Jacob J, Judge BS, Kazzi Z, Kerns WP 2nd, Kim T, Koons A, Leikin JB, Levine M, Liss DB, Marino R, McKay CA, McKeever RG, Meadors K, Moore E, Mullins ME, Nacca N, Nelson ME, Porter L, Riley BD, Ruha AM, Santos C, Schult R, Schwarz ES, Scoccimarro A, Seifert SA, Shafer S, Shah KR, Smolinske SC, Spyres M, Tortora L, Vearrier DJ, Warrick BJ, Weiss S, Wolk BJ, Yanta J.
We also wish to thank study coordinators Andrea Ramirez, D Hopkins, DA Gonzalez, Julie Licata, K Hart, Love Wilson, MD Cook, Melissa Vandenberg, PM Beuhler, T Falter and Tammy Phan.
Funding
The Toxicology Investigators Consortium received funding from the US National Institute of Drug Abuse 1RO1DA037317-02, and data sharing contracts with the U.S. Food and Drug Administration and BTG International, Inc. (North America).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of Interest
None.
Previous presentation of data
This data has not been previously presented.
Additional information
Supervising Editor: Supervising Editor: Mark B. Mycyk, MD
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 484 kb)
Rights and permissions
About this article
Cite this article
Spyres, M.B., Farrugia, L.A., Kang, A.M. et al. The Toxicology Investigators Consortium Case Registry-the 2018 Annual Report. J. Med. Toxicol. 15, 228–254 (2019). https://doi.org/10.1007/s13181-019-00736-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-019-00736-9